AJP - Heart AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 285: H1786-H1789, 2003. First published June 12, 2003; doi:10.1152/ajpheart.00359.2003
0363-6135/03 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/4/H1786    most recent
00359.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lum, H.
Right arrow Articles by Holian, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lum, H.
Right arrow Articles by Holian, O.

REPORTS

Inflammatory stress increases receptor for lysophosphatidylcholine in human microvascular endothelial cells

Hazel Lum,1 Jing Qiao,1 Robert J. Walter,4 Fei Huang,1 Papasani V. Subbaiah,2 Kwang S. Kim,5 and Oksana Holian3

Departments of 1Pharmacology and 2Medicine, Rush-Presbyterian St. Luke's Medical Center; Departments of 3Medicine and 4Surgery, Cook County Hospital, Chicago Illinois, 60612; and 5Department of Pediatrics, The Johns Hopkins University, Baltimore, Maryland 21205

Submitted 21 April 2003 ; accepted in final form 11 June 2003

ABSTRACT

The atherogenic serum lysophosphatidylcholine (LPC) is known to mediate vascular endothelial responses ranging from upregulation of adhesion molecules and growth factors to secretion of chemokines and superoxide anion. We investigated whether endothelial cells express receptors for LPC, which may account for their actions. Human brain microvascular (HBMEC) and dermal microvascular endothelial cells (HMEC) were prepared for RT-PCR analysis for possible expression of the G protein-coupled receptors, GPR4 and G2A, which are believed to be specific LPC receptors. Results indicated that HBMEC expressed low basal GPR4 mRNA, but stimulation with tumor necrosis factor-{alpha} (TNF-{alpha}) (100 U/ml) or H2O2 (50 µmol/l) for 2 h or overnight upregulated expression severalfold. In contrast, HMEC expressed high basal GPR4 mRNA, which was not further increased by either TNF-{alpha} or H2O2 stimulation. Another LPC receptor, G2A, was not detected in either endothelial cell type. Competition binding studies were made to evaluate specific binding of [3H]LPC to the intact endothelial cell monolayer. Basal specific [3H]LPC binding in HBMEC was approximately eight times lower than in HMEC; however, TNF-{alpha} or H2O2 stimulation increased [3H]LPC binding on HMBEC but not HMEC. The results indicated that GPR4 expression was consistent with specific [3H]LPC binding. Overall, we report that endothelial cells selectively expressed GPR4, a specific LPC receptor. Furthermore, GPR4 expression by HBMEC, but not HMEC, was increased by inflammatory stresses. We conclude that endogenous GPR4 in endothelial cells may be a potential G protein-coupled receptor by which LPC signals proinflammatory activities.

G protein-coupled receptors 4 and 2A; oxidants; tumor necrosis factor-{alpha}; specific binding


LYSOPHOSPHATIDYLCHOLINE (LPC) is a proinflammatory and atherogenic serum lysophospholipid that activates a variety of cell types, including the vascular endothelium (6, 8, 9, 13, 15, 24). Endothelial cells stimulated with LPC are shown to upregulate endothelial cell adhesion molecules such as ICAM-1, VCAM-1, and P-selectin (8, 14, 26) and growth factors (17). Moreover, LPC-activated endothelium secretes cytokines, matrix metalloproteinases, , as well as arachidonic acid (4, 7, 20, 21, 23). Thus LPC stimulates multiple inflammatory activities in the vascular endothelium.

LPC can activate several second messenger pathways, including protein kinase C, extracellular signal-regulated kinases, tyrosine kinases, and Ca2+ (2, 16, 19, 26), implicating engagement of transduction mechanisms. Recent evidence suggests that two cloned orphan G protein-coupled receptors, GPR4 and G2A, may be specific LPC receptors in immune and tumor cells (5, 25). In these reports, the ectopically expressed receptors demonstrated high binding affinity and specificity with LPC. The physiological function and endogenous expression of LPC receptors by the vascular endothelium, as well as the consequent pathological implications, have yet to be fully elucidated. The goal of the present study was to investigate the intriguing possibility that endothelium may express endogenous GPR4 and G2A by which LPC mediates inflammatory responses.

MATERIALS AND METHODS

For these studies, we cultured human microvascular endothelial cells from two different vascular beds, brain (HBMEC) and dermis (HMEC). HBMEC were grown in RPMI 1640 supplemented with 10% FBS, 10% NuSerum (Becton Dickinson; Bedford, MA), endothelial cell growth supplement (30 µg/ml), heparin (5 U/ml), 1 mmol/l sodium pyruvate, 1 mmol/l minimal essential media (MEM), nonessential amino acids, 1 mmol/l MEM vitamins, 1% L-glutamine, and 1% penicillin-streptomycin. HMEC were cultured in MCDB 131 medium (GIBCO-BRL; Gaithersburg, MD) supplemented with 5% FBS (Hyclone; Logan, UT), 10 µg/l human epidermal growth factor, 1 mg/l hydrocortisone, 1% penicillin-streptomycin, and 1% L-glutamine. Both HBMEC (18) and HMEC (1, 11) express the endothelial phenotype and demonstrate endothelial functional characteristics.

The expression of GPR4 and G2A mRNAs in HBMEC and HMEC was determined by RT-PCR as described previously (10). Total RNA was extracted from confluent monolayers of HBMEC or HMEC treated for 2 h or overnight with either TNF-{alpha} (100 U/ml) or H2O2 (50 µmol/l), as well as from human lymphocytes as a positive control. Total RNA was reverse transcribed with oligo-dT primers, and PCR was performed with specific primer sets corresponding to GenBank sequences of human GPR4 (5' = CAT CGC CTT CCT GTG CTG CA; 3' = AAG AGC ACG TGA TAG GGC GC) and G2A (5' = ATG TGC CCA ATG CTA CTG; 3' = GTT CAC CGT GGA CAG GCA CA). RT-PCR products were analyzed by 1.5% agarose gel electrophoresis.

Specific binding of LPC (1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine; Avanti Polar Lipids, Alabaster, AL) to endothelial cell surface was determined by competition binding assays. Confluent cell monolayers grown in 24-well culture dishes were treated overnight with either TNF-{alpha} (100 U/ml) or H2O2 (50 µmol/l). The cells were washed and incubated for 60 min at 4°C with HEPES buffer (pH 7.4, 0.1% BSA) containing 0.02 nmol [3H]LPC (L-1-[methyl-3H]lyso-3-phosphatidylcholine; 40–60 Ci/mmol; American Radiolabeled Chemicals, St. Louis, MO) or [3H]LPC plus a 200-fold molar excess of unlabeled LPC. After three washes with cold HEPES buffer, cells were lysed with 0.1 mol/l NaOH, radioactivity was counted, and specific binding from duplicate samples was calculated (as fmol LPC bound/106 cells). Separate dishes of cells were treated in parallel for cell count determination.

RESULTS AND DISCUSSION

A major finding is that human endothelial cells from two different vascular beds, brain and skin, expressed the LPC receptor GPR4 mRNA (Fig. 1) but not G2A mRNA (Fig. 2). This selectivity for GPR4 expression by endothelial cells is consistent with the report that GPR4 appears to have wide tissue distribution, including the ovary, lung, kidney, liver, brain, and lymph nodes (25). Our current finding suggests that this wide distribution in tissue expression extends to the vascular endothelium as well. In contrast, G2A was not expressed by either endothelial cell types but was detected in human lymphocytes serving as a positive control (Fig. 2). This observation is consistent with reports indicating that G2A is found predominantly in tissues rich in lymphocytes such as spleen and thymus and to a lessor extent in other tissues such as the heart and lung (22).



View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1. G protein-coupled receptor (GPR)4 mRNA expression in human microvascular endothelial cells. Cultured monolayers of human brain microvascular (HBMEC) or dermal (HMEC) endothelial cells were treated with 100 U/ml of tumor necrosis factor-{alpha} (TNF-{alpha}) or 50 µmol/l H2O2 for 2 h or overnight, and RT-PCR was performed from extracted total RNA. +Ctrl indicates positive control pAW109 RNA, 302 bp (GeneAmp RNA PCR kit); RT, murine leukemia virus reverse transcriptase; C, untreated control cells; lane 1 = 100 bp DNA ladder; n = 3. Shown are bands at the predicted band size of 419 bp. Subsequent Basic Local Alignment Search Tool analysis of the sequenced bands indicated 96–97% identity with human GPR4 gene database sequences and an E value <10160. Negative controls (reaction performed in absence of RT) indicated absence of contaminating genomic DNA.

 


View larger version (85K):
[in this window]
[in a new window]
 
Fig. 2. Human microvascular endothelial cells do not express G2A mRNA. Total RNA from HBMEC or HMEC treated with 100 U/ml of TNF-{alpha} or 50 µmol/l H2O2 for 2 h or overnight was analyzed by RT-PCR for G2A expression. Extracted RNA from human lymphocytes serve as positive tissue control. Shown are results from HBMEC indicating lack of G2A mRNA detected. Similarly, HMEC did not express G2A mRNA (not shown). Human lymphocytes serving as positive control tissue expressed both G2A and GPR4. Predicted band size for G2A is 899 bp and for GPR4 is 419 bp. +Ctrl indicates positive control pAW109 RNA, 302 bp (GeneAmp RNA PCR kit); negative controls (reaction performed in absence of RT) indicated absence of contaminating genomic DNA.

 

The pattern of constitutive GPR4 mRNA expression by the two endothelial cell types was considerably different. HBMEC expressed barely detectable levels of constitutive GPR4 (the predicted 419-bp product was detected only at increased PCR cycles; data not shown), whereas the basal expression of GPR4 mRNA in HMEC was higher than that in HBMEC. The findings suggest that HMEC may have greater surface expression of endogenous GPR4 protein than HBMEC. Our laboratory is at present developing an antibody to GPR4 to investigate this hypothesis.

We next determined whether inflammatory stress induces GPR4 expression in HBMEC and HMEC. Evidence to date indicates that LPC receptors appear to be inducible by a wide range of signals, including DNA-damaging reagents, stress, and apoptosis (22). HBMEC and HMEC were stimulated by the cytokine TNF-{alpha} or the oxidant H2O2 for 2 h or overnight. The results indicated that in HBMEC, but not HMEC, stimulation with TNF-{alpha} or H2O2 increased GPR4 mRNA over control within 2 h (Fig. 1), which was sustained overnight (data not shown). Subsequent sequencing of the purified bands in both forward and reverse directions (Research Resources Center, University of Illinois at Chicago) and BLAST 2.0 analysis (Basic Local Alignment Search Tool, NCBI) indicated that the GPR4 DNA sequences had 96–97% identity with gene database sequences, corresponding to E values <10160. Thus results indicated that GPR4 was increased by TNF-{alpha} and H2O2 stimuli. Although reasons for the selective upregulation of GPR4 in HBMEC but not in HMEC are not apparent from this study, the findings do suggest that cerebral vascular endothelium appear to be highly sensitive to inflammatory stresses in the context of LPC receptor expression, which may lead to enhanced responsiveness to LPC. In contrast, neither HBMEC (Fig. 2) nor HMEC express G2A, the other LPC receptor; furthermore, TNF-{alpha} or H2O2 was ineffective in induction of its expression.

We also evaluated the relation of GPR4 expression and specific binding of LPC to endothelial cells following inflammatory stress. The binding studies were optimized to evaluate surface binding of LPC on intact cells. The results indicated that HBMEC have greater than eightfold lower basal [3H]LPC binding than HMEC (Table 1), which is consistent with the lower constitutive GPR4 mRNA detected. HBMEC stimulated by TNF-{alpha} or H2O2 overnight showed three- and fivefold increases of [3H]LPC binding over control, respectively (Table 1). The induced increases of [3H]LPC binding were consistent with the increased GPR4 expression found. Overall, the results suggest that [3H]LPC likely bound endogenous GPR4. It is possible that LPC binds to both GPR4 and other closely related receptors because GPR4 shares 30–50% sequence homology with other G protein-coupled receptors such as the platelet activating factor (PAF) receptor (3, 12). However, binding studies indicated that PAF did not compete with LPC binding in cells ectopically expressed with GPR4 (25), indicating that LPC likely did not bind to the PAF receptor. Interestingly, another bioactive phospholipid sphingosylphosphorylcholine has been shown to bind with GPR4 at higher affinity [Michaelis-Menten dissociation constant (Kd)= 36 nM] than LPC (Kd = 159 nM) when investigated in cells ectopically expressed with GPR4 (25), suggesting that endothelial cells may also be activated by SPC through GPR4.


View this table:
[in this window]
[in a new window]
 
Table 1. Specific binding of [3H]LPC to microvascular endothelial cells

 

In conclusion, our results indicated that of the known receptors for LPC to date, vascular endothelial cells selectively expressed GPR4 but not G2A. Furthermore, GPR4 expressed in brain endothelial cells was inducible by inflammatory stresses such as cytokines and oxidants, and this ability appears to be tissue specific. We conclude that the endogenous GPR4 expressed in the endothelium may provide a G protein-coupled receptor mechanism by which the highly proinflammatory LPC signals cellular responses.

DISCLOSURES

This work was supported by National Heart, Lung, and Blood Institute Grants HL-62649 (to H. Lum) and HL-52597 (to P. V. Subbaiah) and by the American Heart Association (to H. Lum).


    FOOTNOTES
 

Address for reprint requests and other correspondence: H. Lum, Dept. of Pharmacology, Rush-Presbyterian St. Luke's Medical Center, 2242 W. Harrison St., Suite 260, Chicago, IL 60612 (E-mail: hlum{at}rush.edu).

FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

REFERENCES

  1. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, and Lawley TJ. HMEC-1-establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99: 683–690, 1992.[Web of Science][Medline]
  2. Chen Y, Morimoto S, Kitano S, Koh E, Fukuo K, Jiang B, Chen S, Yasuda O, Hirotani A, and Ogihara T. Lysophosphatidylcholine causes Ca2+ influx, enhanced DNA synthesis and cytotoxicity in cultured vascular smooth muscle cells. Atherosclerosis 112: 69–76, 1995.[Web of Science][Medline]
  3. Heiber M, Docherty JM, Shah G, Nguyen T, Cheng R, Heng HH, Marchese A, Tsui LC, Shi X, and George SR. Isolation of three novel human genes encoding G protein-coupled receptors. DNA Cell Biol 14: 25–35, 1995.[Web of Science][Medline]
  4. Inoue N, Takeshita S, Gao D, Ishida T, Kawashima S, Akita H, Tawa R, Sakurai H, and Yokoyama M. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 155: 45–52, 2001.[Web of Science][Medline]
  5. Kabarowski JH, Zhu K, Le LQ, Witte ON, and Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293: 702–705, 2001.[Abstract/Free Full Text]
  6. Kohno M, Yokokawa K, Yasunari K, Minami M, Kano H, Hanehira T, and Yoshikawa J. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98: 353–359, 1998.[Abstract/Free Full Text]
  7. Kugiyama K, Sugiyama S, Ogata N, Oka H, Doi H, Ota Y, and Yasue H. Burst production of superoxide anion in human endothelial cells by lysophosphatidylcholine. Atherosclerosis 143: 201–204, 1999.[Web of Science][Medline]
  8. Kume N, Cybulsky MI, and Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90: 1138–1144, 1992.[Web of Science][Medline]
  9. Liu-Wu Y, Hurt-Camejo E, and Wiklund O. Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis 137: 351–357, 1998.[Web of Science][Medline]
  10. Lum H, Hao Z, Gayle D, Kumar P, Patterson CE, and Uhler MD. Vascular endothelial cells express isoforms of protein kinase A inhibitor. Am J Physiol Cell Physiol 282: C59–C66, 2002.[Abstract/Free Full Text]
  11. Lum H, Jaffe HA, Schulz IT, Masood A, RayChaudhury A, and Green RD. Expression of PKA inhibitor (PKI) gene abolishes cAMP-mediated protection to endothelial barrier dysfunction. Am J Physiol Cell Physiol 277: C580–C588, 1999.[Abstract/Free Full Text]
  12. Mahadevan MS, Baird S, Bailly JE, Shutler GG, Sabourin LA, Tsilfidis C, Neville CE, Narang M, and Korneluk RG. Isolation of a novel G protein-coupled receptor (GPR4) localized to chromosome 19q13.3. Genomics 30: 84–88, 1995.[Web of Science][Medline]
  13. Morimoto M, Kume N, Miyamoto S, Ueno Y, Kataoka H, Minami M, Hayashida K, Hashimoto N, and Kita T. Lysophosphatidylcholine induces early growth response factor-1 expression and activates the core promoter of pdgf-a chain in vascular endothelial cells. Arterioscler Thromb Vasc Biol 21: 771–776, 2001.[Abstract/Free Full Text]
  14. Murohara T, Scalia R, and Lefer AM. Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ Res 78: 780–789, 1996.[Abstract/Free Full Text]
  15. Nishioka H, Horiuchi H, Arai H, and Kita T. Lysophosphatidylcholine generates superoxide anions through activation of phosphatidylinositol 3-kinase in human neutrophils. FEBS Lett 441: 63–66, 1998.[Web of Science][Medline]
  16. Ozaki H, Ishii K, Arai H, Kume N, and Kita T. Lysophosphatidylcholine activates mitogen-activated protein kinases by a tyrosine kinase-dependent pathway in bovine aortic endothelial cells. Atherosclerosis 143: 261–266, 1999.[Web of Science][Medline]
  17. Sato N, Kokame K, Shimokado K, Kato H, and Miyata T. Changes of gene expression by lysophosphatidylcholine in vascular endothelial cells: 12 up-regulated distinct genes including 5 cell growth-related, 3 thrombosis-related, and 4 others. J Biochem (Tokyo) 123: 1119–1126, 1998.[Abstract/Free Full Text]
  18. Stins MF, Gilles F, and Kim KS. Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 76: 81–90, 1997.[Web of Science][Medline]
  19. Sugiyama S, Kugiyama K, Ohgushi M, Fujimoto K, and Yasue H. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Role of protein kinase C. Circ Res 74: 565–575, 1994.[Abstract/Free Full Text]
  20. Takahara N, Kashiwagi A, Maegawa H, and Shigeta Y. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabol Clin Exper 45: 559–564, 1996.
  21. Takeshita S, Inoue N, Gao D, Rikitake Y, Kawashima S, Tawa R, Sakurai H, and Yokoyama M. Lysophosphatidylcholine enhances superoxide anions production via endothelial NADH/NADPH oxidase. J Atheroscler Thromb 7: 238–246, 2000.[Medline]
  22. Weng Z, Fluckiger AC, Nisitani S, Wahl MI, Le LQ, Hunter CA, Fernal AA, Le Beau MM, and Witte ON. A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. Proc Natl Acad Sci USA 95: 12334–12339, 1998.[Abstract/Free Full Text]
  23. Wong JT, Tran K, Pierce GN, Chan AC, OK, and Choy PC. Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells. J Biol Chem 273: 6830–6836, 1998.[Abstract/Free Full Text]
  24. Yamakawa T, Tanaka S, Yamakawa Y, Kamei J, Numaguchi K, Motley ED, Inagami T, and Eguchi S. Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 22: 752–758, 2002.[Abstract/Free Full Text]
  25. Zhu K, Baudhuin LM, Hong G, Williams FS, Cristina KL, Kabarowski JH, Witte ON, and Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J Biol Chem 276: 41325–41335, 2001.[Abstract/Free Full Text]
  26. Zhu Y, Lin JH, Liao HL, Verna L, and Stemerman MB. Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta 1345: 93–98, 1997.[Medline]



This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
L. V. Yang, C. G. Radu, M. Roy, S. Lee, J. McLaughlin, M. A. Teitell, M. L. Iruela-Arispe, and O. N. Witte
Vascular Abnormalities in Mice Deficient for the G Protein-Coupled Receptor GPR4 That Functions as a pH Sensor
Mol. Cell. Biol., February 15, 2007; 27(4): 1334 - 1347.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. W. Parks, A. J. Lusis, and J. H.S. Kabarowski
Loss of the Lysophosphatidylcholine Effector, G2A, Ameliorates Aortic Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice
Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2703 - 2709.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Qiao, F. Huang, R. P. Naikawadi, K. S. Kim, T. Said, and H. Lum
Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4
Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L91 - L101.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
N. Watanabe, J. W. Zmijewski, W. Takabe, M. Umezu-Goto, C. L. Goffe, A. Sekine, A. Landar, A. Watanabe, J. Aoki, H. Arai, et al.
Activation of Mitogen-Activated Protein Kinases by Lysophosphatidylcholine-Induced Mitochondrial Reactive Oxygen Species Generation in Endothelial Cells
Am. J. Pathol., May 1, 2006; 168(5): 1737 - 1748.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. Mehta
Lysophosphatidylcholine: an enigmatic lysolipid
Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L174 - L175.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
F. Huang, P. V. Subbaiah, O. Holian, J. Zhang, A. Johnson, N. Gertzberg, and H. Lum
Lysophosphatidylcholine increases endothelial permeability: role of PKC{alpha} and RhoA cross talk
Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L176 - L185.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
B. W. Parks, G. P. Gambill, A. J. Lusis, and J. H. S. Kabarowski
Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low density lipoprotein receptor-deficient mice
J. Lipid Res., July 1, 2005; 46(7): 1405 - 1415.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. V. Yang, C. G. Radu, L. Wang, M. Riedinger, and O. N. Witte
Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A
Blood, February 1, 2005; 105(3): 1127 - 1134.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/4/H1786    most recent
00359.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lum, H.
Right arrow Articles by Holian, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lum, H.
Right arrow Articles by Holian, O.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.